Cargando…

NASH‐related cirrhosis: An occult liver disease burden

Detalles Bibliográficos
Autores principales:	Arrese, Marco, Feldstein, Ariel E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721433/ https://www.ncbi.nlm.nih.gov/pubmed/29335681 http://dx.doi.org/10.1002/hep4.1033

Ejemplares similares

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

The role of oxidized lipid species in insulin resistance and NASH in children
por: Santoro, Nicola, et al.
Publicado: (2022)

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
por: Arrese, Marco, et al.
Publicado: (2021)

Occult endocrine dysfunction in patients with cirrhosis of liver
por: Kumar, K. V. S. Hari, et al.
Publicado: (2016)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future
por: Xie, Chencheng, et al.
Publicado: (2023)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors
por: Zheng, Qianqian, et al.
Publicado: (2023)

Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?
por: Tarantino, Giovanni
Publicado: (2013)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
por: McSweeney, Lorraine, et al.
Publicado: (2020)

Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective
por: Díaz, Luis Antonio, et al.
Publicado: (2022)

NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease
por: Manka, Paul, et al.
Publicado: (2020)

Therapeutic Physical Exercise Programs in the Context of NASH Cirrhosis and Liver Transplantation: A Systematic Review
por: Farrugia, Marwin A., et al.
Publicado: (2023)

Occult Hepatitis B Infection in Patients With Cryptogenic Liver Cirrhosis in Southwest of Iran
por: Hashemi, Seyed Jalal, et al.
Publicado: (2015)

Occult Hepatitis C Virus Infection in Candidates for Liver Transplant With Cryptogenic Cirrhosis
por: Keyvani, Hossein, et al.
Publicado: (2013)

Characterizing the Heterogeneity of Liver Cell Populations Under a NASH-Related Hepatotoxicant Using Single-Nuclei RNA Sequencing
por: Rodrigues, Pedro M., et al.
Publicado: (2020)

NASH: Connecting the dots with patients in mind
por: Cryer, Donna R.
Publicado: (2020)

Something to mTORC About in NASH
por: Finck, Brian N.
Publicado: (2022)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

The burden of liver cirrhosis in mortality: Results from the global burden of disease study
por: Ye, Fei, et al.
Publicado: (2022)

Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis
por: Grizzi, Fabio, et al.
Publicado: (2014)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

Letter from Dr. Nash
por: Hart, James A.
Publicado: (1875)

Targeting bile acids and lipotoxicity for NASH treatment
por: Chiang, John Y. L.
Publicado: (2017)

Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH
por: Povero, Davide, et al.
Publicado: (2020)

Prognostic Assessment and Management of Liver Cirrhosis
por: Qi, Xingshun, et al.
Publicado: (2017)

Diagnostic and Prognostic Markers in Liver Cirrhosis
por: Augustin, Salvador, et al.
Publicado: (2011)

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
por: Golabi, Pegah, et al.
Publicado: (2018)

Occult cardiac amyloidosis?
por: Westin, Oscar, et al.
Publicado: (2019)

Evaluation of Predisposing Metabolic Risk Factors for Portopulmonary Hypertension in Patients with NASH Cirrhosis
por: Türker, Fatih, et al.
Publicado: (2022)

MerTK, a risk factor for NASH fibrosis
por: Wang, Xiaobo, et al.
Publicado: (2020)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
por: Fan, Weiguo, et al.
Publicado: (2021)

NASH and Systemic Complications: From Basic to Clinical Research
por: Baumgartner, Sabine, et al.
Publicado: (2021)

Radiocontrast-induced nephropathy in patients with liver cirrhosis and chronic kidney disease
por: Jo, Sang-Kyung
Publicado: (2012)

Management of chronic liver diseases and cirrhosis: current status and future directions
por: Xu, Jing-Hang, et al.
Publicado: (2020)

Regression of liver cirrhosis: Orthodoxy or paradigm shift?
por: Yu, Su Jong
Publicado: (2015)

Critical issues in the diagnosis and treatment of liver cirrhosis
por: Wang, Xing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vjbelmbhbr19bb0qk89kblt8ti